This Pharma Stock Just Declared An 1800% Dividend – Price Action Suggests More Upside; Buy After Q4 Results?

One of the largest and most rapidly expanding injectable firms, Gland Pharma was founded in Hyderabad in 1978 and has operations in 60 countries, including the US, Europe, Canada, Australia, India, and other markets. It has a strong history in the creation, production, and distribution of sterile injectables and largely uses a business-to-business (B2B) business model. In addition to offering a large variety of injectables, such as ampoules, lyophilized vials, pre-filled syringes, dry powders, infusions, oncology, and ophthalmology solutions, it also holds the honor of being the first company in India to develop Heparin technology.

Gland Pharma Dividend

The Board of Directors "recommended a final dividend of Rs. 18/- (1800%) per equity share of Rs. 1/- each for the financial year 2024-25. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the 47th Annual General Meeting (AGM). Pursuant to Regulation 42 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the record date for the purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025, is Thursday, August 14, 2025," said Gland Pharma in a stock exchange filing.

The 47th Annual General Meeting of the members of the company will be held on Thursday, August 28, 2025.

Gland Pharma Q4 Results

For the fourth quarter of the fiscal year 2024-2025 (Q4 FY25), Gland Pharma's net profit was Rs 187 crore, down 3% YoY from Rs 192 crore in the same quarter last year. In addition, revenue from operations fell 7% YoY to Rs 1,425 crore in Q4 FY25 from Rs 1,538 crore in Q4 FY24. Additionally, EBITDA (earnings before interest, tax, depreciation, and amortization) decreased 3% YoY from Rs 359 crore to Rs 348 crore. In the March 2025 quarter, the EBITDA margin increased slightly from 23% in the same time last year to 24% in the quarter under review.

Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, said, "FY25 was a year of strategic realignment and investment in future growth. Through the year we mitigated many challenges and strengthened the core by advancing key pillars of manufacturing, quality, and R&D. Our approach involves expanding our core business into new emerging markets, carefully enhancing our manufacturing capabilities to encompass complex injectables and novel delivery systems and building pipeline through our robust in-house research and development efforts. Our progress in biologies CDMO and collaborations with leading partners reflect our intent to diversify and grow beyond traditional segments. H/e remain firmly focused on executing the Cenexi turnaround and leveraging targeted M&A to drive long-term, sustainable value for all stakeholders."

Mr. Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, ''In Q4 FY25 our consolidated revenue reached INR 14,249 million, with a healthy EBITDA margin of 24%. On the base business the EBITDA margin expanded to 38%>, driven by volume traction in our U.S. portfolio and high-margin new product launches. Cenexi posted modest sequential improvement in revenue & gross margin and we remain firmly committed to its turnaround. Looking ahead, our strategic focus is on accelerating growth in RoW and India, deepening our U.S. presence through portfolio enhancement, and continuing to lead on quality and cost efficiency."

Gland Pharma Share Price Target

"Gland Pharma has rebounded sharply in recent sessions, with immediate support now at ₹1520. Resistance is seen near ₹1600, and a break above could take it to ₹1650. The stock has formed a short-term bullish pattern and is trading above key moving averages. Momentum indicators support further upside, and traders can consider buying near ₹1550-₹1560 with a stop-loss at ₹1500. A move past ₹1600 would confirm continuation of the current uptrend," commented Riyank Arora - Technical Analyst - Mehta Equities Limited.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.